Clinical Trial Update: Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant nivolumab and lirilumab, followed by surgery and adjuvant nivolumab and lirilumab for squamous cell carcinoma of the head a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• OPDIVO (nivolumab)
• lirilumab (lirilumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-06-16